pioglitazone has been researched along with Degenerative Disc Disease in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Y | 1 |
| Qu, Y | 1 |
| Liu, L | 1 |
| Zhao, H | 1 |
| Ma, H | 1 |
| Si, M | 1 |
| Cheng, L | 1 |
| Nie, L | 1 |
1 other study available for pioglitazone and Degenerative Disc Disease
| Article | Year |
|---|---|
PPAR-γ agonist pioglitazone protects against IL-17 induced intervertebral disc inflammation and degeneration via suppression of NF-κB signaling pathway.
Topics: Adult; Aged; Anti-Inflammatory Agents; Cytokines; Female; Humans; Intervertebral Disc Degeneration; | 2019 |